<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>ar1638</ui>
   <ji>ARJ</ji>
   <fm>
      <dochead>Poster presentation</dochead>
      <bibl>
         <title>
            <p>Association of <it>FCGR2A </it>and Fc gamma receptor haplotypes with Spanish polymyalgia rheumatica and giant cell arteritis</p>
         </title>
         <aug>
            <au id="A1">
               <snm>Morgan</snm>
               <fnm>AW</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A2">
               <snm>Gonzalez-Gay</snm>
               <fnm>MA</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A3">
               <snm>Robinson</snm>
               <fnm>JI</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A4">
               <snm>Babbage</snm>
               <fnm>SJ</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A5">
               <snm>Haroon-Rashid</snm>
               <fnm>L</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A6">
               <snm>Hajeer</snm>
               <fnm>AH</fnm>
               <insr iid="I3"/>
            </au>
            <au id="A7">
               <snm>Ollier</snm>
               <fnm>WER</fnm>
               <insr iid="I3"/>
            </au>
            <au id="A8">
               <snm>Isaacs</snm>
               <fnm>JD</fnm>
               <insr iid="I1"/>
               <insr iid="I4"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Academic Unit of Musculoskeletal Disease and Molecular Medicine Unit, University of Leeds, UK</p>
            </ins>
            <ins id="I2">
               <p>Rheumatology Division, Hospital Xeral-Calde, Lugo, Spain</p>
            </ins>
            <ins id="I3">
               <p>The Centre for Integrated Genomic Medical Research, The University of Manchester, UK</p>
            </ins>
            <ins id="I4">
               <p>School of Clinical Medical Sciences (Rheumatology), University of Newcastle-Upon-Tyne, UK</p>
            </ins>
         </insg>
         <source>Arthritis Research &amp; Therapy</source>
         <supplement>
            <title>
               <p>25<sup>th</sup> European Workshop for Rheumatology Research</p>
            </title>
            <sponsor>
               <note>The organizer would like to thank the following companies who have generously supported the meeting: Abbott Immunology (Main sponsor), Bristol-Myers Squibb, Schering-Plough, Wyeth, AstraZeneca, MSD, Amgen</note>
            </sponsor>
            <note>Meeting abstracts</note>
         </supplement>
         <conference>
            <title>
               <p>25<sup>th</sup> European Workshop for Rheumatology Research</p>
            </title>
            <location>Glasgow, UK</location>
            <date-range>24-27 February 2005</date-range>
         </conference>
         <issn>1478-6354</issn>
         <pubdate>2005</pubdate>
         <volume>7</volume>
         <issue>Suppl 1</issue>
         <fpage>P117</fpage>
         <xrefbib>
            <pubid idtype="doi">10.1186/ar1638</pubid>
         </xrefbib>
      </bibl>
      <history>
         <rec>
            <date>
               <day>11</day>
               <month>1</month>
               <year>2005</year>
            </date>
         </rec>
         <pub>
            <date>
               <day>17</day>
               <month>2</month>
               <year>2005</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2005</year>
         <collab>BioMed Central Ltd</collab>
      </cpyrt>
   </fm>
   <bdy>
      <sec>
         <st>
            <p>Background</p>
         </st>
         <p>Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are two inflammatory diseases that are thought to arise from a complex interaction between multiple genetic factors and environmental triggers. We have previously demonstrated an association between the Fc gamma receptor (Fc&#947;R) genetic locus on chromosome 1q22-23 and rheumatoid arthritis, and have now extended our study to include other inflammatory/autoimmune diseases.</p>
      </sec>
      <sec>
         <st>
            <p>Methods</p>
         </st>
         <p>The <it>FCGR2A-131H/R</it>, <it>FCGR3A-158F/V </it>and <it>FCGR3B-NA1/NA2 </it>functional polymorphisms and a novel <it>FCGR2B </it>3'-UTR polymorphism were examined for association with PMR (<it>n </it>= 69) and GCA (<it>n </it>= 83) in two well-characterised clinical cohorts from Northern Spain. In view of the close molecular proximity between <it>FCGR2A</it>, <it>FCGR3A</it>, <it>FCGR3B </it>and <it>FCGR2B </it>we have examined Fc&#947;R haplotypes for association with rheumatoid arthritis. Pairwise disequilibrium coefficients (<it>D'</it>) were initially calculated in 115 matched controls. The EHPlus program was used to estimate haplotype frequencies for patients and controls and to determine whether significant linkage disequilibrium was present. A likelihood ratio test is performed to test for differences between the haplotype frequencies in cases and controls. A permutation procedure implemented in this program enabled 1000 permutations to be performed on all haplotype associations to assess significance.</p>
      </sec>
      <sec>
         <st>
            <p>Results</p>
         </st>
         <p>There was borderline linkage disequilibrium between <it>FCGR2A </it>and <it>FCGR3A </it>(<it>D' </it>= -0.313, <it>P </it>= 0.03) with more significant disequilibrium between <it>FCGR3A </it>and <it>FCGR3B </it>(<it>D' </it>= -0.646, <it>P </it>= 0.0001). There was a significant difference in the <it>FCGR2A </it>allele (<it>P </it>= 0.03) and genotype frequencies (<it>P </it>= 0.03) with GCA compared with controls. Specifically, there was an increase in the <it>FCGR2A</it>-131RR genotype in both the PMR (odds ratio [OR] = 2.15; 95% confidence interval [CI] = 1.0&#8211;4.7, <it>P </it>= 0.05) and GCA (OR = 2.53, 95% CI = 1.3&#8211;5.1, <it>P </it>= 0.01) populations compared with controls.</p>
         <p>Increased homozygosity for the <it>FCGR2A</it>-<it>FCGR3A </it>131R-158F haplotype was found in 8% controls compared with 25% of PMR (OR = 4.20, 95% CI = 1.3&#8211;13.1, <it>P </it>= 0.01) and 24% GCA (OR = 4.46, 95% CI = 1.5&#8211;3.3, <it>P </it>= 0.004) individuals. Logistic regression analyses suggested that both <it>FCGR2A </it>and <it>FCGR3A </it>contributed to GCA susceptibility. In addition, homozygosity for the <it>FCGR3A</it>-<it>FCGR3B </it>158F-NA2 haplotype was found in 25% controls compared with 44% GCA subjects (OR = 2.35, 95% CI = 1.0&#8211;5.7, <it>P </it>= 0.06). Logistic regression analyses suggested that <it>FCGR3A </it>was the most important site contributing to GCA susceptibility.</p>
         <p>A subgroup of GCA patients who had experienced visual symptoms was examined as a marker of disease severity. The most significant findings were increased homozygosity of a <it>FCGR2A</it>-<it>FCGR3A </it>131R-158F haplotype (8% controls, 16% GCA without visual manifestations and 50% GCA with visual manifestations [OR = 12.86, 95% CI = 1.3&#8211;128.2, <it>P </it>= 0.03]). Additionally, the <it>FCGR3A</it>-<it>FCGR3B </it>haplotype was found in 11/13 individuals who sustained visual manifestations. Homozygosity was seen in 25% controls, 27% GCA without eye involvement and 63% GCA with visual manifestations (OR = 5.83, 95% CI = 0.9&#8211;38.9, <it>P </it>= 0.08). For each haplotype logistic regression analyses suggested <it>FCGR3A </it>was the most important site.</p>
      </sec>
      <sec>
         <st>
            <p>Conclusions</p>
         </st>
         <p>We have demonstrated that <it>FCGR2A </it>may contribute to the 'susceptibility' of PMR and GCA in this Spanish population. The increased association observed with a <it>FCGR2A</it>-<it>FCGR3A </it>haplotype suggests the presence of additional genetic polymorphisms in linkage disequilibrium with this haplotype that may contribute to disease susceptibility. In addition, Fc&#947;R haplotypes may potentially define a subpopulation of individuals at greater risk of vascular occlusion. These findings may ultimately provide new insights into disease pathogenesis.</p>
      </sec>
   </bdy>
   <bm>
      <ack>
         <sec>
            <st>
               <p>Acknowledgement</p>
            </st>
            <p>This work was funded by The Health Foundation.</p>
         </sec>
      </ack>
   </bm>
</art>
